Is ADMA Biologics a Good Coronavirus Stock to Buy Now?
The number of authorized coronavirus treatment options increased by one over the weekend, and the market's already pushing up shares of companies that could see a related revenue bump. The Food and Drug Administration's recent emergency use authorization (EUA) of convalescent plasma for the treatment of COVID-19 sent shares of ADMA Biologics (NASDAQ: ADMA) soaring in anticipation of a huge revenue bump.
Can this convalescent plasma stock continue climbing? Here's what investors should know.
Image source: Getty Images.
Source Fool.com
